Peer-Reviewed Articles
Researchers Conduct NH Studies for Rare Diseases and Drug Development
By Thomas Ogorka, Gajendra Chanchu
The use of Natural History studies in order to examine a rare disease that will help facilitate drug development programs.
Monitoring Temperature Control Throughout IMP Supply Journey
How a single-source temperature management strategy can support a drug’s quality and integrity in transit—a process as important as the destination.
The Enrollment Rescue Dilemma: How Sponsors and Sites Can Make the Most of a Tough Situation
Survey uncovers key best practices that sponsors, CROs, and sites should consider when faced with patient enrollment challenges.
Comply with ICH E6 (R2)
The ICH E6 (R2) GCP Guideline became final in November 2016. As noted in the Guideline, since the original ICH E6 (R1) was released, clinical trials were performed in a largely paper-based process. E6 (R2) was developed to address the increased scale, complexity, and cost of clinical trials, and to include the advances that have been made in electronic data recording and reporting technologies, as well as the implementation of other approaches and, in fact, encourages the implementation of improved and more efficient approaches to clinical trial design, conduct, oversight, recording and reporting while continuing to ensure human subject protection and reliability of trial results.
The articles can help ensure your GCP is up to par in the areas included in the ICH E6 (R2).
Data Analysis
Pinpointing Phase III Trials in Emerging Countries
Most clinical trial activity for Phase III trials takes place in the traditional North American and European markets.
How Important is Big Data?
Survey collects thoughts from industry professionals on the current and future impact of big data in clinical trials.
Measuring the Added Time of Complicated Phase III Studies
This analysis uses a large dataset to forecast the study completion time costs of specific protocol designs and execution plans.
ACT TV
Events
Interactive Response Technologies in Clinical Trials 2017
October 26 - 27, 2017
Philadelphia, Pennsylvania
Blogs
FDA Seeks Patient Input on Strategies to Increase Trial Enrollment & Improve Study Design
FDA advisory committee made up of patients comes together to improve clinical trials and product development through better study design and greater participation.
Clinical Trials Confusing—Even to Doctors
Most physicians and many specialists have limited understanding of clinical trial data and research findings presented in prescription drug promotional materials for professional audiences.
New mHealth Action Plan Released
The Duke Margolis Center for Health Policy (DMCHP) recently collaborated with the FDA to release an mHealth action plan entitled "Mobilizing mHealth Innovation for Real-World Evidence Generation."
Noteworthy
New Role To Improve Clinical Trial Performance
With several systems existing to measure performance, the most significant are the course of patient recruitment, how many patients complete the study, as well as the quality of the data generated.
Latest Business and People News
By Applied Clinical Trials Editors
Updated employee announcements, business news, awards, and recognition in the industry today.
Vaccine-Induced Specific Immune Response Offers an Avenue to Potentiate Responses to Immune Checkpoint Inhibitor Therapy
Cancer vaccine-based immunotherapy may help overcome the resistance of certain tumors to immune checkpoint inhibitors, while immune checkpoint inhibitors may enhance the efficacy of cancer vaccine therapies.
eBooks
Clinical Trials for Rare Diseases
This eBook will focus on advancing research, drug development, and trial management in rare diseases. Articles cover considerations from virtual trials and eCOA to the case for highly-skilled CRAs.
Webcasts
Sponsored Links
